Chemoenzymatic syntheses of homo- and heterodimers of AZT and d4T, and evaluation of their anti-HIV Activity

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 4, 2004, Pages 701-714

  Taourirte, M ^a   Ait Mohamed, L ^b   Rochdi, A ^b   Vasseur, J J ^c   Fernandez S ^d   Ferrero, M ^d   Gotor, V ^d   Pannecouque, C ^e   De Clercq, E ^e   Lazrek, H B ^b  

^a FACULTÉ DES SCIENCES ET TECHNIQUES GUÉLIZ   (Morocco)

^b FACULTÉ DES SCIENCES SEMLALIA   (Morocco)

^c UNIVERSITÉ DE MONTPELLIER   (France)

^d UNIVERSITY OF OVIEDO   (Spain)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AZT; Chemoenzymatic syntheses; d4T; Homo and heterodimers

Indexed keywords

CARBAMIC ACID; CARBAMIC ACID DERIVATIVE; CARBONIC ACID; CARBONIC ACID DERIVATIVE; DIMER; STAVUDINE; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DIMERIZATION; FUNGAL PROTEINS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; LIPASE; STAVUDINE; VIRUS REPLICATION; ZIDOVUDINE;

ANIMALIA; HOMO; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 2542624354     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-120037749     Document Type: Article

References (27)

1. Barré-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868-871.
2. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev., Drug Discov. 2002, 1, 13-25.
3. De Clercq, E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
4. Richman, D.D.; Fischl, M.A.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, G.G.; Durack, D.T.; Nusinoff-Lehrman, S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, 192-197.
5. Pollard, R.B. d4T nucleoside combinations for HIV. Antivir. Res. 1996, 29, 101-104.
6. Rosowsky, A.; Fu, H.; Pai, N.; Mellors, J.; Richman, D.D.; Hostetler, K.Y. Synthesis and in vitro activity of long-chain 5′ -O-[(alkoxycarbonyl)phosphinyl]-3′-azido-3′-deoxythymidines against wild-type and AZT-and foscarnect-resistant strains of HIV-1. J. Med. Chem. 1997, 40, 2482-2490.
7. Vlieghe, P.; Bihel, F.; Clerc, T.; Pannecouque, C.; Witvrouw, M.; De Clercq, E.; Salles, J.P.; Chermann, J.C.; Krauss, J.L. New 3′ -Azido-3′-deoxythymidin-5′-yl-O-(ω-hydroxyalkyl) carbonate prodrogues: synthesis and anti-HIV evaluation. J. Med. Chem. 2001, 44, 777-786, and references cited therein.
8. Routledge, A.; Walker, I.; Freeman, S.; Hay, A.; Mahmood, N. Synthesis, bioactivation and anti-HIV activity of 4-acyloxybenzylbis(nucleosid-5′ -yl)phosphates. Nucleosides Nucleotides 1995, 14, 1545-1558.
9. Matsumoto, H.; Matsuda, T.; Nakata, S.; Mitoguchi, T.; Kimura, T.; Hayashi, Y.; Kiso, Y. Synthesis and biological evaluation of prodrogue-type anti-HIV agents: ester conjugates of carboxylic acid-containing dipeptide HIV protease inhibitors and a reverse transcriptase inhibitor. Bioorg. Med. Chem. 2001, 9, 417-430.
10. Matsumoto, H.; Kimura, T.; Hamawaki, T.; Kumagai, A.; Goto, T.; Sano, K. ; Hayashi, Y.; Kiso, Y. Design, synthesis and biological evaluation of anti-HIV double-drugs: conjugates of HIV protease inhibitors with a reverse transcriptase inhibitors through spontaneously cleavable linkers. Bioorg. Med. Chem. 2001, 9, 1589-1600.
11. Tamamura, H.; Omagari, A.; Hiramatsu, K.; Kanamoto, T.; Gotoh, K.; Kanbara, K.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation. Bioorg. Med. Chem. 2001, 9, 2179-2187.
12. Taourirte, M.; Lazrek, H.B.; Vasseur, J.J.; Fernández, S.; Ferrero, M.; Gotor, V. Synthesis of new homo and heterodinucleosides containing the 2′,3′-dideoxynucleosides AZT and D4T. Nucleosides Nucleotides 2001, 20, 959-962.
13. Ferrero, M.; Gotor, V. Biocatalytic selective modifications of conventional nucleosides, carbocyclic nucleosides, and C-nucleosides. Chem. Rev. 2000, 100, 4319-4347.
14. Ferrero, M.; Gotor, V. Chemoenzymatic transformations in nucleoside chemistry. Monatsh. Chem. 2000, 131, 585-616.
15. 3 C-5 A-ring carbamate derivatives. J. Org. Chem. 1997, 62, 4358-4363.
16. Magdalena, J.; Fernández, S.; Ferrero, M.; Gotor, V. Chemoenzymatic synthesis of novel 3′-carbazoyl nucleoside derivatives. Regioselective preparation of 3′- and 5′-Alkyliden carbazoyl nucleosides. J. Org. Chem. 1998, 63, 8873-8879.
17. Gotor-Fernández, V.; Ferrero, M.; Fernández, S.; Gotor, V. 1α,25-Dihydroxyvitamin D3 A-ring precursors: studies on regioselective enzymatic alkoxycarbonylation reaction of their stereoisomers. Chemoenzymatic synthesis of A-ring synthon carbamate derivatives, including carbazates and polyamino carbamates. J. Org. Chem. 1999, 64, 7504-7510.
18. Magdalena, J.; Fernández, S.; Ferrero, M.; Gotor, V. Synthesis of novel carbazoyl linked pyrimidine-pyrimidine and pyrimidine-purine dinucleoside analogues. Tetrahedron Lett. 1999, 40, 1787-1790.
19. Zimmerman, T.P.; Mahoney, W.B.; Prus, K.L. 3′-Azido-3′ -deoxy-thymidine. An unusual nucleoside analogue that permeates the membrane of human-erythrocytes and lymphocytes by non facilitated diffusion. J. Biol. Chem. 1987, 262, 5748-5754.
20. Hansch, C.; Steward, A.R.; Anderson, S.M.; Bentley, D. The parabolic dependence of drug action upon lipophilic character as revealed by study of hypnotics. J. Med. Chem. 1968, 11, 1-11.
21. Rey, F.; Barré-Sinoussi, F.; Schmidtmayerova, H.; Chermann, J.C. Detection and titration of neutralizing antibodies to HIV using an inhibition of the cytopathic effect of the virus on MT4 cells. J. Virol. Methods 1987, 16, 239-249.
22. Rey, F.; Donker, G.; Hirsch, I.; Chermann, J.C. Productive infection of CD4+ cells by selected HIV strains is not inhibited by anti-CD4 monoclonal antibodies. Virology 1993, 18, 165-171.
23. Schott, H.; Ludwig, P.S.; Immelmann, A.; Schwendener, R.A. Synthesis and in vitro anti-HIV activities of amphiphilic heterodinucleoside phosphate derivatives containing the 2′,3′-dideoxynucleosides ddc, AZT and ddI. Eur. J. Med. Chem. 1999, 34, 343-352.
24. Ijichi, K.; Fujiwara, M.; Mori, K.; Morozumi, M.; Machida, H.; Shigeta, S.; Konno, K.; Yokota, T.; Baba, M. Antiviral activities of nucleoside heterodimers against human immunodeficiency virus type 1 in vivo. Antivir. Res. 1996, 31, 115-120.
25. Popovic, M.; Sangadharan, M.G.; Read, E.; Gallo, R.C. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.
26. Harada, S.; Koyanagi, Y.; Yamanoto, N. Infection of HTLV-III/LAV in HTL carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985, 229, 563-566.
27. Collins, L.A.; Franzblau, S.G. Microplate alamar blue assay versus BACTEC 460 system for high-through out screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997, 41, 1004-1009.